Q3 EPS Forecast for Agilent Technologies Raised by Analyst

Agilent Technologies, Inc. (NYSE:A - Free Report) - Investment analysts at Leerink Partnrs upped their Q3 2025 EPS estimates for Agilent Technologies in a research note issued to investors on Wednesday, December 18th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings per share of $1.42 for the quarter, up from their previous estimate of $1.41. The consensus estimate for Agilent Technologies' current full-year earnings is $5.56 per share. Leerink Partnrs also issued estimates for Agilent Technologies' Q1 2026 earnings at $1.49 EPS, Q2 2026 earnings at $1.43 EPS, Q3 2026 earnings at $1.52 EPS and Q4 2026 earnings at $1.66 EPS.

A has been the subject of several other reports. Bank of America reduced their price objective on Agilent Technologies from $153.00 to $150.00 and set a "neutral" rating for the company in a research note on Friday, December 13th. Stifel Nicolaus reaffirmed a "buy" rating and set a $151.00 price target on shares of Agilent Technologies in a report on Monday, August 26th. StockNews.com lowered shares of Agilent Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, November 26th. JPMorgan Chase & Co. cut their price objective on shares of Agilent Technologies from $165.00 to $160.00 and set an "overweight" rating for the company in a research report on Tuesday, November 26th. Finally, Wells Fargo & Company lowered their target price on shares of Agilent Technologies from $157.00 to $155.00 and set an "overweight" rating on the stock in a report on Monday, December 9th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Agilent Technologies currently has a consensus rating of "Hold" and a consensus price target of $143.62.

Agilent Technologies Stock Performance

A traded up $0.09 during trading on Monday, hitting $134.60. 1,194,923 shares of the stock were exchanged, compared to its average volume of 1,734,785. The company has a quick ratio of 1.58, a current ratio of 2.09 and a debt-to-equity ratio of 0.57. Agilent Technologies has a 1-year low of $124.16 and a 1-year high of $155.35. The stock has a fifty day moving average price of $135.85 and a two-hundred day moving average price of $136.50. The firm has a market capitalization of $38.67 billion, a P/E ratio of 30.45, a PEG ratio of 4.48 and a beta of 1.07.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Monday, November 25th. The medical research company reported $1.46 EPS for the quarter, beating analysts' consensus estimates of $1.41 by $0.05. The company had revenue of $1.70 billion for the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The company's quarterly revenue was up .8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.38 EPS.

Agilent Technologies Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 22nd. Investors of record on Tuesday, December 31st will be issued a $0.248 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $0.99 dividend on an annualized basis and a yield of 0.74%. This is a boost from Agilent Technologies's previous quarterly dividend of $0.24. Agilent Technologies's dividend payout ratio (DPR) is presently 22.40%.

Insider Buying and Selling at Agilent Technologies

In related news, SVP Dominique Grau sold 9,990 shares of Agilent Technologies stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the transaction, the senior vice president now owns 40,011 shares in the company, valued at approximately $5,801,595. The trade was a 19.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.33% of the stock is owned by company insiders.

Institutional Investors Weigh In On Agilent Technologies

Several hedge funds and other institutional investors have recently bought and sold shares of A. Crewe Advisors LLC raised its stake in shares of Agilent Technologies by 114.8% in the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company's stock valued at $25,000 after purchasing an additional 101 shares in the last quarter. Livelsberger Financial Advisory acquired a new stake in Agilent Technologies during the third quarter valued at approximately $28,000. Ridgewood Investments LLC bought a new position in Agilent Technologies during the 2nd quarter worth approximately $29,000. Ashton Thomas Securities LLC acquired a new position in shares of Agilent Technologies in the 3rd quarter worth approximately $31,000. Finally, Fortitude Family Office LLC increased its holdings in shares of Agilent Technologies by 68.3% in the 3rd quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company's stock valued at $35,000 after acquiring an additional 95 shares during the last quarter. 87.42% of the stock is currently owned by hedge funds and other institutional investors.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.